Hymecromone clinical trial is cautiously positive

Jul 7, 2025

1 min read

A very small (16 patients) phase 2a clinical trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD) looked at whether hymecromone, a drug that might help blood vessels, had any promising effects.

Overall, the results weren't statistically significant, but half the patients treated with hymecromone improved their six-minute walk distance by 66m and had improved quality of life. Researchers concluded that a larger trial is warranted.

Read the Thorax article

Recent Posts

Why men with systemic sclerosis-associated PAH fare worse

Men with systemic sclerosis and pulmonary arterial hypertension (PAH) tend to have more heart-related complications and lower survival rates. Differences in the effects of hormones such as estrogen an

First two patients enrolled in a clinical trial to treat Group 2 PH

A press release announced that the first two patients have enrolled in a trial of a treatment for Group 2 pulmonary hypertension (PH associated with left heart disease). The treatment procedure is min

Animal research shows miR-224 contributes to PAH

A small molecule called microRNA-224-5p (miR-224) appears to play an important role in the changes to the lung blood vessels that occur in pulmonary arterial hypertension (PAH). Researchers found that

Comments